Background Most patients with metastatic non-small cell lung cancer (NSCLC) will face
treatment with systemic therapy. Current clinical studies are demonstrating improvements in …

BACKGROUND New therapies for metastatic non–small cell lung cancer (NSCLC) have
improved survival in clinical trials. However, only a minority of patients receive systemic …

Introduction Multiple therapeutic options now exist for metastatic non–small-cell lung cancer
(mNSCLC). In this study we evaluated treatment patterns and outcomes in mNSCLC …

Controversy persists as to whether systemic chemotherapy is beneficial treatment for stage
IV non-small cell lung cancer (NSCLC). Combination chemotherapy used to treat patients …

Lung cancer is one of the main causes of cancer related deaths. Approximately three
quarters of these tumors are non-small cell carcinomas. When diagnosed the majority of …

Objectives: Metastatic non–small cell lung cancer (NSCLC) has a poor prognosis. Most
patients present with stage IV, and many patients treated curatively with stage I to III develop …

Purpose. Significant advances in the systemic management of metastatic non‐small cell
lung cancer (NSCLC) have occurred over the past decade, with options now including …

Objective: To review the current practices for metastatic non–small cell lung cancer (NSCLC)
management and highlight the latest progress. Data Sources: A literature review using …

Objectives: To compare the clinical characteristics and outcomes between relapsed and de
novo metastatic non–small cell lung cancer (NSCLC). Materials and Methods: We reviewed …

Background Patients with metastatic non-small-cell lung cancer (NSCLC) who survive more
than 2 years are considered long-term survivors (LTSs). The present study examined factors …